| Literature DB >> 30793376 |
Ayelet Grupper1,2, Doron Schwartz2, Roni Baruch1,2, Idit F Schwartz2, Richard Nakache1, Yaacov Goykhman1, Polina Katz1, Angelina Lebedinsky1, Ido Nachmany1, Nir Lubezky1, Jessie Aouizerate1, Moshe Shashar2,3, Helena Katchman1,4.
Abstract
Inflammatory bowel diseases (IBD) is a systemic disorder with possible renal involvement, yet data regarding the outcome of kidney transplantation (KT) in those patients, and IBD course post KT, are scarce. In this retrospective analysis, we studied the outcome of 12 IBD kidney recipients (seven Crohn's disease, five ulcerative colitis; primary kidney disease was IgA nephropathy in five, polycystic disease in four), compared to two control groups: matched controls and a cohort of recipients with similar kidney disease. During a follow-up period of 60.1 (11.0-76.6) months (median, interquartile range), estimated 5-year survival was 80.8 vs. 96.8%, with and without IBD, respectively (P = 0.001). Risk of death with a functioning graft was higher with IBD (HR = 1.441, P = 0.048), and with increased age (HR = 1.109, P = 0.05). Late rehospitalization rate was higher in IBD [incidence rate ratio = 1.168, P = 0.030], as well as rate of hospitalization related to infection [1.42, P = 0.037]. All patients that were in remission before KT, remission was maintained. Patients that were transplanted with mild or moderate disease remained stable or improved with Infliximab or Adalimumab treatment. In conclusion, IBD is associated with an increased risk of mortality, hospitalization because of infection and late rehospitalization after KT. Clinical course of IBD is stable after KT.Entities:
Keywords: inflammatory bowel disease; kidney transplantation
Mesh:
Substances:
Year: 2019 PMID: 30793376 DOI: 10.1111/tri.13415
Source DB: PubMed Journal: Transpl Int ISSN: 0934-0874 Impact factor: 3.782